About Mirum Pharmaceuticals, Inc.
https://www.mirumpharma.comMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
CEO
Christopher Peetz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 144
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:6.8M
Value:$615.98M
JANUS HENDERSON GROUP PLC
Shares:5M
Value:$453.03M
BLACKROCK, INC.
Shares:3.6M
Value:$326.56M
Summary
Showing Top 3 of 297
About Mirum Pharmaceuticals, Inc.
https://www.mirumpharma.comMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $133.01M ▲ | $104.87M ▼ | $2.9M ▲ | 2.18% ▲ | $0.06 ▲ | $9.06M ▲ |
| Q2-2025 | $127.78M ▲ | $109.35M ▲ | $-5.86M ▲ | -4.59% ▲ | $-0.12 ▲ | $4.19M ▲ |
| Q1-2025 | $111.58M ▲ | $103.75M ▲ | $-14.68M ▲ | -13.15% ▲ | $-0.3 ▲ | $-4M ▲ |
| Q4-2024 | $99.41M ▲ | $100.86M ▲ | $-23.79M ▼ | -23.93% ▼ | $-0.49 ▼ | $-14.73M ▼ |
| Q3-2024 | $90.38M | $82.25M | $-14.23M | -15.75% | $-0.3 | $-4.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $375.55M ▲ | $785.12M ▲ | $493.07M ▲ | $292.05M ▲ |
| Q2-2025 | $304.55M ▲ | $725.83M ▲ | $470.67M ▲ | $255.16M ▲ |
| Q1-2025 | $277.67M ▼ | $690.25M ▲ | $456.99M ▲ | $233.26M ▲ |
| Q4-2024 | $280.31M ▼ | $670.75M ▲ | $445.11M ▲ | $225.64M ▼ |
| Q3-2024 | $284.44M | $667.89M | $435.87M | $232.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.9M ▲ | $39.68M ▲ | $-2.23M ▲ | $16.1M ▲ | $53.9M ▲ | $39.49M ▲ |
| Q2-2025 | $-5.86M ▲ | $12.04M ▲ | $-6.6M ▲ | $8.69M ▲ | $16.36M ▲ | $11.91M ▲ |
| Q1-2025 | $-14.68M ▲ | $-1.96M ▲ | $-16.13M ▼ | $6.36M ▲ | $-10.68M ▼ | $-2M ▲ |
| Q4-2024 | $-23.79M ▼ | $-5.07M ▼ | $641K ▲ | $5.34M ▲ | $-466K ▲ | $-5.09M ▲ |
| Q3-2024 | $-14.23M | $3.98M | $-18.04M | $3.86M | $-10.1M | $-6.2M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $180.00M ▲ | $110.00M ▼ | $130.00M ▲ | $130.00M ▲ |
 License and Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Rest of World | $0 ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
 UNITED STATES | $80.00M ▲ | $90.00M ▲ | $100.00M ▲ | $100.00M ▲ |
 Rest Of The World | $60.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Christopher Peetz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 144
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:6.8M
Value:$615.98M
JANUS HENDERSON GROUP PLC
Shares:5M
Value:$453.03M
BLACKROCK, INC.
Shares:3.6M
Value:$326.56M
Summary
Showing Top 3 of 297